The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
[Alprenolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; AG 1879 inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; AG 1879 inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; AG 1879 inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Alprenolol binds to and results in decreased activity of ADRB1 protein; Alprenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Alprenolol inhibits the reaction [cyanopindolol binds to ADRB1 protein]; Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]; Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]; Alprenolol promotes the reaction [ADRB1 protein binds to ARRB1 protein]; Alprenolol promotes the reaction [ADRB1 protein binds to ARRB2 protein]; Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of and results in increased uptake of EGFR protein]; ARRB1 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB1 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; ARRB2 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB2 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; CGP 20712A affects the reaction [Alprenolol results in increased activity of ADRB1 protein]; HBEGF protein inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; HBEGF protein inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; HBEGF protein promotes the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased uptake of EGFR protein]]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]] [Alprenolol results in increased phosphorylation of ADRB1 protein] which results in increased phosphorylation of EGFR protein; Alprenolol results in increased phosphorylation of ADRB1 protein
[Alprenolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Alprenolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein; [Alprenolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein; [Alprenolol co-treated with ADRB2 protein] results in increased expression of GNAS protein; Alprenolol inhibits the reaction [cyanopindolol binds to ADRB2 protein] Alprenolol inhibits the reaction [ADRB2 results in decreased susceptibility to Histamine]; Alprenolol inhibits the reaction [ADRB2 results in increased expression of GRK2 protein]
[Alprenolol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; Alprenolol binds to and results in increased activity of ADRB3 protein; Alprenolol inhibits the reaction [cyanopindolol binds to ADRB3 protein]
[Alprenolol co-treated with ARRB1 protein] results in increased expression of MIR125A mRNA; [Alprenolol co-treated with ARRB1 protein] results in increased expression of MIR125B-1 mRNA; [Alprenolol co-treated with ARRB1 protein] results in increased expression of MIR150 mRNA; [Alprenolol co-treated with ARRB1 protein] results in increased expression of MIR214 mRNA; Alprenolol promotes the reaction [ADRB1 protein binds to ARRB1 protein]; ARRB1 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB1 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]
Alprenolol promotes the reaction [ADRB1 protein binds to ARRB2 protein]; ARRB2 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB2 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]
AG 1879 inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; AG 1879 inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; AG 1879 inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]; Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]; Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of and results in increased uptake of EGFR protein]; ARRB1 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB1 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; ARRB2 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB2 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; HBEGF protein inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; HBEGF protein inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; HBEGF protein promotes the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased uptake of EGFR protein]]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]] [Alprenolol results in increased phosphorylation of ADRB1 protein] which results in increased phosphorylation of EGFR protein
HBEGF protein inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; HBEGF protein inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; HBEGF protein promotes the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]
[Alprenolol co-treated with Cocaine] affects the reaction [HTR2A protein results in increased susceptibility to 4-iodo-2,5-dimethoxyphenylisopropylamine]
[Alprenolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein; AG 1879 inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]; ARRB1 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB2 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; HBEGF protein inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]] Erlotinib Hydrochloride inhibits the reaction [Alprenolol results in increased phosphorylation of MAPK1 protein]
[Alprenolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein; AG 1879 inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]; ARRB1 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; ARRB2 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; HBEGF protein inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]] Erlotinib Hydrochloride inhibits the reaction [Alprenolol results in increased phosphorylation of MAPK3 protein]
[Alprenolol co-treated with ARRB1 protein] results in increased expression of MIR125B-1 mRNA Alprenolol results in increased expression of MIR125B-1 mRNA
Alprenolol inhibits the reaction [Hydralazine results in increased expression of REN protein] Alprenolol results in decreased expression of REN protein
Atenolol inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Atenolol results in decreased activity of ABCB11 protein
Atenolol results in decreased activity of ADRB1 protein Atenolol binds to and results in decreased activity of ADRB1 protein; Atenolol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Atenolol inhibits the reaction [Dihydroalprenolol binds to ADRB1 protein] Atenolol binds to ADRB1 protein [Atenolol binds to and results in decreased activity of ADRB1 protein] inhibits the reaction [Nicotine results in increased expression of PTGS2 protein]; [Atenolol binds to and results in decreased activity of ADRB1 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; [Atenolol binds to and results in decreased activity of ADRB1 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [Atenolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Atenolol binds to and results in decreased activity of ADRB1 protein] which results in decreased susceptibility to Nicotine; [Atenolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; Atenolol binds to and results in decreased activity of ADRB1 protein; Atenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [CGP 12177 results in increased activity of ADRB1 protein]; Atenolol inhibits the reaction [cyanopindolol binds to ADRB1 protein]; Atenolol inhibits the reaction [Isoproterenol results in increased activity of ADRB1 protein] ADRB1 protein polymorphism affects the susceptibility to Atenolol Atenolol results in decreased expression of ADRB1 mRNA
Atenolol results in increased expression of ADRB2 protein Atenolol binds to ADRB2 protein Atenolol binds to and results in decreased activity of ADRB2 protein; Atenolol inhibits the reaction [CGP 12177 binds to ADRB2 protein]; Atenolol inhibits the reaction [Dihydroalprenolol binds to ADRB2 protein] [Atenolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Atenolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein; [Atenolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein; [Atenolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; Atenolol binds to and results in decreased activity of ADRB2 protein; Atenolol inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [Albuterol binds to and results in increased activity of ADRB2 protein]; Atenolol inhibits the reaction [cyanopindolol binds to ADRB2 protein]; Atenolol inhibits the reaction [Epinephrine binds to and results in increased activity of ADRB2 protein]; Atenolol inhibits the reaction [Isoproterenol binds to and results in increased activity of ADRB2 protein]; Atenolol inhibits the reaction [Terbutaline binds to and results in increased activity of ADRB2 protein]
Atenolol inhibits the reaction [Apomorphine results in increased secretion of and results in increased activity of AMY1A protein]; Atenolol inhibits the reaction [Cisplatin results in increased secretion of and results in increased activity of AMY1A protein]; Atenolol inhibits the reaction [Isoproterenol results in increased secretion of and results in increased activity of AMY1A protein]; Atenolol inhibits the reaction [Lithium Chloride results in increased secretion of and results in increased activity of AMY1A protein]
Atenolol inhibits the reaction [Isoproterenol results in decreased activity of CAT protein]; Atenolol promotes the reaction [Quercetin inhibits the reaction [Isoproterenol results in decreased activity of CAT protein]]; Atenolol promotes the reaction [Thyroxine results in decreased expression of CAT protein]; Quercetin promotes the reaction [Atenolol inhibits the reaction [Isoproterenol results in decreased activity of CAT protein]]
Atenolol inhibits the reaction [Dopamine results in increased activity of G6PD protein]; Atenolol inhibits the reaction [Isoproterenol results in increased activity of G6PD protein]
[Atenolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein; [Atenolol binds to and results in decreased activity of ADRB1 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; Atenolol inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of MAPK1 protein]
[Atenolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein; [Atenolol binds to and results in decreased activity of ADRB1 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; Atenolol inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of MAPK3 protein]
Atenolol inhibits the reaction [Carvedilol inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Atenolol inhibits the reaction [Carvedilol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Atenolol inhibits the reaction [Dopamine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Atenolol inhibits the reaction [Dopamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Atenolol inhibits the reaction [Epinephrine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Atenolol inhibits the reaction [Epinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Atenolol inhibits the reaction [Norepinephrine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Atenolol inhibits the reaction [Norepinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]
[Atenolol co-treated with Doxazosin] results in decreased expression of NPPB mRNA; [Atenolol co-treated with Losartan co-treated with Doxazosin] results in decreased expression of NPPB mRNA Atenolol results in decreased expression of NPPB mRNA Atenolol results in increased expression of NPPB protein
[Atenolol binds to and results in decreased activity of ADRB1 protein] inhibits the reaction [Nicotine results in increased expression of PTGS2 protein]
[aliskiren co-treated with Atenolol] results in decreased activity of REN protein; [Dexamethasone co-treated with Nifedipine co-treated with Atenolol co-treated with Antihypertensive Agents] results in increased secretion of REN protein Atenolol results in decreased expression of REN protein Atenolol inhibits the reaction [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in increased expression of REN protein]; Atenolol inhibits the reaction [2-hexynyladenosine-5'-N-ethylcarboxamide results in increased expression of REN protein] Atenolol results in decreased activity of REN protein
Atenolol inhibits the reaction [Epinephrine results in increased activity of SOD1 protein] Atenolol promotes the reaction [Thyroxine results in decreased expression of SOD1 protein]
Atenolol inhibits the reaction [Epinephrine results in increased activity of SOD2 protein] Atenolol inhibits the reaction [Thyroxine results in increased expression of SOD2 protein]
Betaxolol affects the reaction [Cocaine affects the expression of ADRB1 protein]; Betaxolol inhibits the reaction [Cocaine affects the expression of ADRB1 protein] Betaxolol binds to ADRB1 protein Betaxolol binds to and results in decreased activity of ADRB1 protein
[Betaxolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; Betaxolol binds to and results in decreased activity of ADRB2 protein
Betaxolol results in decreased cleavage of CASP3 protein Betaxolol results in increased expression of CASP3 protein ABT-737 inhibits the reaction [Betaxolol results in decreased cleavage of CASP3 protein]
benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Betaxolol results in increased expression of CASP8 protein]
Betaxolol results in increased expression of and results in increased phosphorylation of MLKL protein; necrostatin-1 inhibits the reaction [Betaxolol results in increased expression of and results in increased phosphorylation of MLKL protein]
Betaxolol results in increased expression of RIPK3 protein necrostatin-1 inhibits the reaction [Betaxolol results in increased expression of RIPK3 protein]
ABCB1 protein results in increased transport of Bisoprolol Bisoprolol inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; valspodar inhibits the reaction [ABCB1 protein results in increased transport of Bisoprolol]
Bisoprolol results in decreased activity of ADRB1 protein Bisoprolol results in increased expression of ADRB1 mRNA [Bisoprolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; Bisoprolol binds to and results in decreased activity of ADRB1 protein; Bisoprolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Bisoprolol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Bisoprolol inhibits the reaction [cyanopindolol binds to ADRB1 protein] Bisoprolol binds to ADRB1 protein
[Bisoprolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Bisoprolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; Bisoprolol binds to and results in decreased activity of ADRB2 protein; Bisoprolol inhibits the reaction [cyanopindolol binds to ADRB2 protein] Bisoprolol results in increased expression of ADRB2 mRNA
Carteolol results in increased expression of and results in increased phosphorylation of ATM protein Carteolol results in increased expression of ATM mRNA
[1,3-dipropyl-8-(2-amino-4-chlorophenyl)xanthine binds to and results in decreased activity of ADORA1 protein] which results in decreased susceptibility to Clonidine
Clonidine binds to and results in increased activity of ADRA2A protein [5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine results in decreased activity of ADRA2A protein] which results in decreased susceptibility to Clonidine
[[CYP2D6 gene polymorphism results in decreased activity of CYP2D6 protein] which results in decreased metabolism of Clonidine] which results in decreased chemical synthesis of 4-hydroxyclonidine; [CYP2D6 gene polymorphism results in decreased activity of CYP2D6 protein] which results in decreased metabolism of Clonidine; [CYP2D6 protein results in increased metabolism of Clonidine] which results in increased chemical synthesis of 4-hydroxyclonidine
Clonidine inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased expression of FOS protein]
Clonidine results in increased secretion of GH1 protein Cocaine inhibits the reaction [Clonidine results in increased secretion of GH1 protein] L 657743 inhibits the reaction [Clonidine results in increased expression of GH1 protein] Clonidine results in increased expression of GH1; Clonidine results in increased expression of GH1 protein
BRL 44408 inhibits the reaction [Clonidine inhibits the reaction [Zymosan results in increased expression of IFNG protein]]; Clonidine inhibits the reaction [Zymosan results in increased expression of IFNG protein]
BRL 44408 inhibits the reaction [Clonidine inhibits the reaction [Zymosan results in increased expression of IL1A protein]]; Clonidine inhibits the reaction [Zymosan results in increased expression of IL1A protein]
Clonidine inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; Clonidine inhibits the reaction [IL1B protein results in increased secretion of CXCL8 protein] BRL 44408 inhibits the reaction [Clonidine inhibits the reaction [Zymosan results in increased expression of IL1B protein]]; Clonidine inhibits the reaction [Zymosan results in increased expression of IL1B protein]
BRL 44408 inhibits the reaction [Clonidine inhibits the reaction [Zymosan results in increased expression of IL2 protein]]; Clonidine inhibits the reaction [Zymosan results in increased expression of IL2 protein]
Clonidine inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; Clonidine inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of and results in increased activity of NFKB1 protein]
[Naloxone binds to and results in decreased activity of OPRM1 protein] which results in decreased susceptibility to Clonidine OPRM1 results in increased susceptibility to Clonidine
Clonidine results in increased expression of POMC protein [Clonidine co-treated with Naloxone co-treated with Morphine] results in increased secretion of POMC protein; Capsaicin inhibits the reaction [[Clonidine co-treated with Naloxone co-treated with Morphine] results in increased secretion of POMC protein]; Indomethacin inhibits the reaction [Clonidine results in increased secretion of POMC protein alternative form] Clonidine results in decreased expression of POMC protein [Clonidine results in increased expression of POMC protein] which results in increased susceptibility to Naloxone
Clonidine inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; Clonidine inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of and results in increased activity of RELA protein]
Clonidine results in increased activity of REN protein Clonidine results in decreased activity of REN protein Clonidine results in decreased expression of REN protein [Clonidine co-treated with Spironolactone] results in decreased expression of REN protein
Clonidine inhibits the reaction [SLC22A2 protein results in increased transport of 1-Methyl-4-phenylpyridinium]; Clonidine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]
Clonidine inhibits the reaction [SLC22A3 protein results in increased transport of 1-Methyl-4-phenylpyridinium]; Clonidine inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium analog] Clonidine inhibits the reaction [SLC22A3 protein results in increased uptake of Tetraethylammonium] Clonidine inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]
Clonidine results in increased activity of TAAR1 protein [Clonidine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP
[Clonidine results in decreased activity of and results in decreased expression of TH protein] which results in decreased abundance of Dopamine; [Clonidine results in decreased activity of and results in decreased expression of TH protein] which results in decreased abundance of Norepinephrine; [Clonidine results in increased expression of TH protein] which results in increased abundance of Epinephrine; [Clonidine results in increased expression of TH protein] which results in increased abundance of Norepinephrine; Clonidine results in decreased activity of and results in decreased expression of TH protein; Clonidine results in increased activity of and results in increased expression of TH protein
BRL 44408 inhibits the reaction [Clonidine inhibits the reaction [Zymosan results in increased expression of TNF protein]]; Clonidine inhibits the reaction [Zymosan results in increased expression of TNF protein]
[1,3-dipropyl-8-(2-amino-4-chlorophenyl)xanthine binds to and results in decreased activity of ADORA1 protein] which results in decreased susceptibility to Clonidine
Clonidine binds to and results in increased activity of ADRA2A protein [5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine results in decreased activity of ADRA2A protein] which results in decreased susceptibility to Clonidine
CYP2D6 protein results in increased metabolism of Clonidine [[CYP2D6 gene polymorphism results in decreased activity of CYP2D6 protein] which results in decreased metabolism of Clonidine] which results in decreased chemical synthesis of 4-hydroxyclonidine; [CYP2D6 gene polymorphism results in decreased activity of CYP2D6 protein] which results in decreased metabolism of Clonidine; [CYP2D6 protein results in increased metabolism of Clonidine] which results in increased chemical synthesis of 4-hydroxyclonidine
Clonidine inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased expression of FOS protein]
Clonidine results in increased secretion of GH1 protein Cocaine inhibits the reaction [Clonidine results in increased secretion of GH1 protein] L 657743 inhibits the reaction [Clonidine results in increased expression of GH1 protein] Clonidine results in increased expression of GH1; Clonidine results in increased expression of GH1 protein
BRL 44408 inhibits the reaction [Clonidine inhibits the reaction [Zymosan results in increased expression of IFNG protein]]; Clonidine inhibits the reaction [Zymosan results in increased expression of IFNG protein]
BRL 44408 inhibits the reaction [Clonidine inhibits the reaction [Zymosan results in increased expression of IL1A protein]]; Clonidine inhibits the reaction [Zymosan results in increased expression of IL1A protein]
Clonidine inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; Clonidine inhibits the reaction [IL1B protein results in increased secretion of CXCL8 protein] BRL 44408 inhibits the reaction [Clonidine inhibits the reaction [Zymosan results in increased expression of IL1B protein]]; Clonidine inhibits the reaction [Zymosan results in increased expression of IL1B protein]
BRL 44408 inhibits the reaction [Clonidine inhibits the reaction [Zymosan results in increased expression of IL2 protein]]; Clonidine inhibits the reaction [Zymosan results in increased expression of IL2 protein]
Clonidine inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; Clonidine inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of and results in increased activity of NFKB1 protein]
[Naloxone binds to and results in decreased activity of OPRM1 protein] which results in decreased susceptibility to Clonidine OPRM1 results in increased susceptibility to Clonidine
Clonidine results in increased expression of POMC protein [Clonidine co-treated with Naloxone co-treated with Morphine] results in increased secretion of POMC protein; Capsaicin inhibits the reaction [[Clonidine co-treated with Naloxone co-treated with Morphine] results in increased secretion of POMC protein]; Indomethacin inhibits the reaction [Clonidine results in increased secretion of POMC protein alternative form] Clonidine results in decreased expression of POMC protein [Clonidine results in increased expression of POMC protein] which results in increased susceptibility to Naloxone
Clonidine inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; Clonidine inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of and results in increased activity of RELA protein]
Clonidine results in increased activity of REN protein Clonidine results in decreased activity of REN protein Clonidine results in decreased expression of REN protein [Clonidine co-treated with Spironolactone] results in decreased expression of REN protein
Clonidine inhibits the reaction [SLC22A2 protein results in increased transport of 1-Methyl-4-phenylpyridinium]; Clonidine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]
Clonidine inhibits the reaction [SLC22A3 protein results in increased transport of 1-Methyl-4-phenylpyridinium]; Clonidine inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium analog] Clonidine inhibits the reaction [SLC22A3 protein results in increased uptake of Tetraethylammonium] Clonidine inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]
Clonidine results in increased activity of TAAR1 protein [Clonidine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP
[Clonidine results in decreased activity of and results in decreased expression of TH protein] which results in decreased abundance of Dopamine; [Clonidine results in decreased activity of and results in decreased expression of TH protein] which results in decreased abundance of Norepinephrine; [Clonidine results in increased expression of TH protein] which results in increased abundance of Epinephrine; [Clonidine results in increased expression of TH protein] which results in increased abundance of Norepinephrine; Clonidine results in decreased activity of and results in decreased expression of TH protein; Clonidine results in increased activity of and results in increased expression of TH protein
BRL 44408 inhibits the reaction [Clonidine inhibits the reaction [Zymosan results in increased expression of TNF protein]]; Clonidine inhibits the reaction [Zymosan results in increased expression of TNF protein]
[1,3-dipropyl-8-(2-amino-4-chlorophenyl)xanthine binds to and results in decreased activity of ADORA1 protein] which results in decreased susceptibility to Clonidine
Clonidine binds to and results in increased activity of ADRA2A protein [5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine results in decreased activity of ADRA2A protein] which results in decreased susceptibility to Clonidine
CYP2D6 protein results in increased metabolism of Clonidine [[CYP2D6 gene polymorphism results in decreased activity of CYP2D6 protein] which results in decreased metabolism of Clonidine] which results in decreased chemical synthesis of 4-hydroxyclonidine; [CYP2D6 gene polymorphism results in decreased activity of CYP2D6 protein] which results in decreased metabolism of Clonidine; [CYP2D6 protein results in increased metabolism of Clonidine] which results in increased chemical synthesis of 4-hydroxyclonidine
Clonidine inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased expression of FOS protein]
Clonidine results in increased secretion of GH1 protein Cocaine inhibits the reaction [Clonidine results in increased secretion of GH1 protein] L 657743 inhibits the reaction [Clonidine results in increased expression of GH1 protein] Clonidine results in increased expression of GH1; Clonidine results in increased expression of GH1 protein
BRL 44408 inhibits the reaction [Clonidine inhibits the reaction [Zymosan results in increased expression of IFNG protein]]; Clonidine inhibits the reaction [Zymosan results in increased expression of IFNG protein]
BRL 44408 inhibits the reaction [Clonidine inhibits the reaction [Zymosan results in increased expression of IL1A protein]]; Clonidine inhibits the reaction [Zymosan results in increased expression of IL1A protein]
Clonidine inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; Clonidine inhibits the reaction [IL1B protein results in increased secretion of CXCL8 protein] BRL 44408 inhibits the reaction [Clonidine inhibits the reaction [Zymosan results in increased expression of IL1B protein]]; Clonidine inhibits the reaction [Zymosan results in increased expression of IL1B protein]
BRL 44408 inhibits the reaction [Clonidine inhibits the reaction [Zymosan results in increased expression of IL2 protein]]; Clonidine inhibits the reaction [Zymosan results in increased expression of IL2 protein]
Clonidine inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; Clonidine inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of and results in increased activity of NFKB1 protein]
[Naloxone binds to and results in decreased activity of OPRM1 protein] which results in decreased susceptibility to Clonidine OPRM1 results in increased susceptibility to Clonidine
Clonidine results in increased expression of POMC protein [Clonidine co-treated with Naloxone co-treated with Morphine] results in increased secretion of POMC protein; Capsaicin inhibits the reaction [[Clonidine co-treated with Naloxone co-treated with Morphine] results in increased secretion of POMC protein]; Indomethacin inhibits the reaction [Clonidine results in increased secretion of POMC protein alternative form] Clonidine results in decreased expression of POMC protein [Clonidine results in increased expression of POMC protein] which results in increased susceptibility to Naloxone
Clonidine inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; Clonidine inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of and results in increased activity of RELA protein]
Clonidine results in increased activity of REN protein Clonidine results in decreased activity of REN protein Clonidine results in decreased expression of REN protein [Clonidine co-treated with Spironolactone] results in decreased expression of REN protein
Clonidine inhibits the reaction [SLC22A2 protein results in increased transport of 1-Methyl-4-phenylpyridinium]; Clonidine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]
Clonidine inhibits the reaction [SLC22A3 protein results in increased transport of 1-Methyl-4-phenylpyridinium]; Clonidine inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium analog] Clonidine inhibits the reaction [SLC22A3 protein results in increased uptake of Tetraethylammonium] Clonidine inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]
Clonidine results in increased activity of TAAR1 protein [Clonidine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP
[Clonidine results in decreased activity of and results in decreased expression of TH protein] which results in decreased abundance of Dopamine; [Clonidine results in decreased activity of and results in decreased expression of TH protein] which results in decreased abundance of Norepinephrine; [Clonidine results in increased expression of TH protein] which results in increased abundance of Epinephrine; [Clonidine results in increased expression of TH protein] which results in increased abundance of Norepinephrine; Clonidine results in decreased activity of and results in decreased expression of TH protein; Clonidine results in increased activity of and results in increased expression of TH protein
BRL 44408 inhibits the reaction [Clonidine inhibits the reaction [Zymosan results in increased expression of TNF protein]]; Clonidine inhibits the reaction [Zymosan results in increased expression of TNF protein]
CYP2D6 gene mutant form affects the metabolism of and affects the hydroxylation of Debrisoquin; Paroxetine inhibits the reaction [CYP2D6 gene mutant form results in decreased susceptibility to Debrisoquin]; Paroxetine inhibits the reaction [CYP2D6 gene mutant form results in increased abundance of Debrisoquin metabolite] CYP2D6 protein results in increased metabolism of Debrisoquin CYP2D6 protein results in increased hydroxylation of Debrisoquin CYP2D6 protein affects the metabolism of Debrisoquin; CYP2D6 protein polymorphism affects the metabolism of Debrisoquin CYP2D6 gene mutant form results in decreased metabolism of Debrisoquin; CYP2D6 gene polymorphism results in decreased metabolism of Debrisoquin
Dihydroergotamine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] Dihydroergotamine results in decreased activity of CYP1A1 protein Dihydroergotamine results in increased activity of CYP1A1 protein
Labetalol results in decreased activity of ADRB1 protein Labetalol binds to ADRB1 protein Labetalol binds to and results in decreased activity of ADRB1 protein; Labetalol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Labetalol inhibits the reaction [Dihydroalprenolol binds to ADRB1 protein] [Labetalol co-treated with ADRB1] results in increased abundance of Cyclic AMP; CGP 20712A inhibits the reaction [[Labetalol co-treated with ADRB1] results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [Labetalol results in increased activity of ADRB1 protein]
Labetalol results in decreased activity of ADRB2 protein Labetalol binds to ADRB2 protein [Labetalol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Labetalol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein; [Labetalol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein Labetalol binds to and results in decreased activity of ADRB2 protein; Labetalol inhibits the reaction [CGP 12177 binds to ADRB2 protein]; Labetalol inhibits the reaction [Dihydroalprenolol binds to ADRB2 protein]
[Uridine Diphosphate Glucuronic Acid co-treated with UGT2B7 protein] results in increased glucuronidation of Labetalol; Fluconazole inhibits the reaction [[Uridine Diphosphate Glucuronic Acid co-treated with UGT2B7 protein] results in increased glucuronidation of Labetalol]
[Nadolol co-treated with Mifepristone] promotes the reaction [methyldithiocarbamate promotes the reaction [Lipopolysaccharides results in increased secretion of IL10 protein]]
[Nadolol co-treated with Mifepristone] inhibits the reaction [methyldithiocarbamate inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein]]
browse the term
